

The following listing of claims is provided for the Examiner's convenient reference.
No claim amendments are presented herein.

Listing of Claims:

1. (Previously Presented) A method of removal of abnormal infective prion proteins associated with transmissible spongiform encephalopathies (TSEs) from an aqueous liquid containing a natural product, which consists essentially of passing the liquid through a depth filter formed of a matrix comprising (a) a binder and (b) kieselguhr or perlite particles or mixtures thereof and having a pore size providing a retention less than 6 μm , and so removing abnormal infective prion proteins which may be present in the liquid such that the liquid is non-infective with respect to prion protein infectivity, wherein the depth filter is a single use filter.

2. (Canceled)

3. (Previously Presented) The method according to claim 1, wherein the binder is cellulose.

4-5. (Canceled)

6. (Previously Presented) The method according to claim 1, carried out in the absence of cationic or anionic charged material.

7. (Previously Presented) The method according to claim 1 carried out at a pH in the range 4 to 10.

8. (Previously Presented) The method according to claim 1, wherein the pore size is in the range 0.6 to 6 microns.

9. (Previously Presented) The method according to claim 1, wherein the pore size is in the range 0.6 to 1.5 microns.

10. (Previously Presented) The method according to claim 1, wherein the depth filter has a thickness of 2 to 5 mm.

11. (Previously Presented) The method according to claim 1, wherein the natural product is a protein.

12. (Previously Presented) The method according to claim 1, wherein the aqueous liquid comprises a blood plasma product derived from human plasma.

13. (Previously Presented) The method according to claim 12, wherein the blood plasma product is selected from the group consisting of albumin, an immunoglobulin, Factor IX, thrombin, fibronectin, fibrinogen, Factor VIII, Factor II, Factor VII, Factor IX, and Factor X.

14. (Previously Presented) A liquid subjected to prion removal according to the method of claim 1.

15. (Previously Presented) The method according to claim 1, wherein the aqueous liquid comprises an animal-derived product selected from the group consisting of heparin and hormones.

16. (Previously Presented) The method according to claim 1, wherein the abnormal infective prion protein is associated with conditions selected from the group consisting of Creutzfeldt-Jakob Disease, variant Creutzfeldt-Jakob Disease, bovine spongiform encephalopathy and scrapie.

17-24. (Canceled)

25. (Previously Presented) The method according to claim 12, wherein the blood plasma product is selected from the group consisting of immunoglobulins and albumin.

26-27. (Canceled)

28. (Previously Presented) The method of claim 1, wherein the filter is pretreated with ethanol.

29-30. (Canceled)

31. (Previously Presented) A method of removal of abnormal infective prion proteins associated with transmissible spongiform encephalopies (TSEs) from an aqueous liquid containing a natural product, which consists essentially of passing the liquid through a depth filter pretreated with ethanol and formed of a matrix comprising (a) a binder and (b) kieselguhr or perlite particles or mixtures thereof and having a pore size providing a retention less than 6 μm , and so removing abnormal infective prion proteins which may be present in the liquid such that the liquid is non-infective with respect to prion protein infectivity.

32. (Previously Presented) The method of claim 1, wherein the depth filter has a permeability of 110 or 220 $\text{L}/\text{m}^2/\text{min}$.